News
![Eilt: Biotech Aktientip startet Phase 2b-Studie zur Behandlung von Hautkrebs. Jetzt 525% mit Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 525% mit Biote: https://www.irw-press.at/prcom/images/messages/2023/73055/Aktiencheck191223.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG4yYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0382e9304419818262958cf390be4ff6af2a173a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aktiencheck191223.001.png?locale=us)
Eilt: Biotech Aktientip startet Phase 2b-Studie zur Behandlung von Hautkrebs. Jetzt 525% mit Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 525% mit Biote
Biotech Aktientip startet Phase 2b-Hautkrebs-Studie. Jetzt 525% mit Biotech Hot Stock nach 15.973% mit BioNTech ($BTNX)
19.12.23
London (www.aktiencheck.de, Anzeige)
Link
![Eilt: Biotech Aktientip startet Phase 2b-Studie zur Behandlung von Hautkrebs. Jetzt 525% mit Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 525% mit Biote: https://www.irw-press.at/prcom/images/messages/2023/73055/Aktiencheck191223.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG4yYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0382e9304419818262958cf390be4ff6af2a173a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aktiencheck191223.001.png?locale=us)
Eilt: Biotech Aktientip startet Phase 2b-Studie zur Behandlung von Hautkrebs. Jetzt 525% mit Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 525% mit Biote
Biotech Aktientip startet Phase 2b-Hautkrebs-Studie. Jetzt 525% mit Biotech Hot Stock nach 15.973% mit BioNTech ($BTNX)
19.12.23
London (www.aktiencheck.de, Anzeige)
Link
![Eilt: Biotech Aktientip startet Phase 2b-Studie zur Behandlung von Hautkrebs. Jetzt 525% mit Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 525% mit Biote: https://www.irw-press.at/prcom/images/messages/2023/73055/Aktiencheck191223.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG4yYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0382e9304419818262958cf390be4ff6af2a173a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aktiencheck191223.001.png?locale=us)
Eilt: Biotech Aktientip startet Phase 2b-Studie zur Behandlung von Hautkrebs. Jetzt 525% mit Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 525% mit Biote
Biotech Aktientip startet Phase 2b-Hautkrebs-Studie. Jetzt 525% mit Biotech Hot Stock nach 15.973% mit BioNTech ($BTNX)
19.12.23
London (www.aktiencheck.de, Anzeige)
Link
![Quick list of bargain stocks to end the year: https://www.marketbeat.com/logos/articles/med_20231215043651_quick-list-of-bargain-stocks-to-end-the-year.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNC96YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ff92670faaed45f2492ef9db3a102f27e43b4194/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231215043651_quick-list-of-bargain-stocks-to-end-the-year.jpg?locale=us)
Quick list of bargain stocks to end the year
Here's a quick economics lesson to return to the good old college days. When markets think that a country's GDP is set to grow in the future, they will turn bullish (massively bullish) toward
![Quick list of bargain stocks to end the year: https://www.marketbeat.com/logos/articles/med_20231215043651_quick-list-of-bargain-stocks-to-end-the-year.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNC96YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ff92670faaed45f2492ef9db3a102f27e43b4194/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231215043651_quick-list-of-bargain-stocks-to-end-the-year.jpg?locale=us)
Quick list of bargain stocks to end the year
Here's a quick economics lesson to return to the good old college days. When markets think that a country's GDP is set to grow in the future, they will turn bullish (massively bullish) toward
![AbbVie continues shopping spree with biotech buyout: https://www.marketbeat.com/logos/articles/med_20231212074517_abbvie-continues-shopping-spree-with-biotech-buyou.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmp2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6eafcfb8da2fb15843e211c46e91e1b47be47190/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231212074517_abbvie-continues-shopping-spree-with-biotech-buyou.jpg?locale=us)
AbbVie continues shopping spree with biotech buyout
Christmas came early for Cerevel Therapeutics shareholders courtesy of AbbVie Inc. (NYSE:ABBV).
Last week, AbbVie announced a plan to acquire the Massachusetts-based biotechnology company in an
![3 biotech powerhouses poised to thrive amidst sector rebound: https://www.marketbeat.com/logos/articles/med_20231208085353_3-biotech-powerhouses-poised-to-thrive-amidst-sect.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMG5zYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--67afff63310fa8abbe501b0adbe50281d9e896b6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231208085353_3-biotech-powerhouses-poised-to-thrive-amidst-sect.jpg?locale=us)
3 biotech powerhouses poised to thrive amidst sector rebound
The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant
![3 biotech powerhouses poised to thrive amidst sector rebound: https://www.marketbeat.com/logos/articles/med_20231208085353_3-biotech-powerhouses-poised-to-thrive-amidst-sect.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMG5zYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--67afff63310fa8abbe501b0adbe50281d9e896b6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231208085353_3-biotech-powerhouses-poised-to-thrive-amidst-sect.jpg?locale=us)
3 biotech powerhouses poised to thrive amidst sector rebound
The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant
![3 biotech powerhouses poised to thrive amidst sector rebound: https://www.marketbeat.com/logos/articles/med_20231208085353_3-biotech-powerhouses-poised-to-thrive-amidst-sect.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMG5zYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--67afff63310fa8abbe501b0adbe50281d9e896b6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231208085353_3-biotech-powerhouses-poised-to-thrive-amidst-sect.jpg?locale=us)
3 biotech powerhouses poised to thrive amidst sector rebound
The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant
![Simply Good Foods: Winner in the Ozempic Weight-Loss Trend: https://www.marketbeat.com/logos/articles/med_20231203163352_chart-smpl2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMzNwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2762bf404e64a2fbf04f8c14dadec64f0cab0f28/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231203163352_chart-smpl2.jpg?locale=us)
Simply Good Foods: Winner in the Ozempic Weight-Loss Trend
Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication trend led by Ozempic, Novo Nordisk A/S (NYSE: NVO)
![Simply Good Foods: Winner in the Ozempic Weight-Loss Trend: https://www.marketbeat.com/logos/articles/med_20231203163352_chart-smpl2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMzNwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2762bf404e64a2fbf04f8c14dadec64f0cab0f28/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231203163352_chart-smpl2.jpg?locale=us)
Simply Good Foods: Winner in the Ozempic Weight-Loss Trend
Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication trend led by Ozempic, Novo Nordisk A/S (NYSE: NVO)
![Ozempic vs. Mounjaro:: Battle of the bulge: https://www.marketbeat.com/logos/articles/med_20231204090609_battle-of-the-bulge-ozempic-vs.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWZuYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a39a099341ade1b6b421b1b2b1e8cacee042fec7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231204090609_battle-of-the-bulge-ozempic-vs.jpg?locale=us)
Ozempic vs. Mounjaro:: Battle of the bulge
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused
![Ozempic vs. Mounjaro:: Battle of the bulge: https://www.marketbeat.com/logos/articles/med_20231204090609_battle-of-the-bulge-ozempic-vs.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWZuYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a39a099341ade1b6b421b1b2b1e8cacee042fec7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231204090609_battle-of-the-bulge-ozempic-vs.jpg?locale=us)
Ozempic vs. Mounjaro:: Battle of the bulge
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused
![Mega merger in the works? Humana, Cigna explore big deal: https://www.marketbeat.com/logos/articles/med_20231201154241_mega-merger-in-the-works-humana-cigna-explore-big.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHZsYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f0e54b22f4366b59a8485b6e113a963b5b9f062a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231201154241_mega-merger-in-the-works-humana-cigna-explore-big.jpg?locale=us)
Mega merger in the works? Humana, Cigna explore big deal
Consolidation in the health insurance industry has become a theme of 2023. Humana Inc. (NYSE: HUM) is reportedly in talks to merge with The Cigna Group (NYSE: CI) in a stock-and-cash deal
![J&J, Gilead, BMS: A look at undervalued dividend payers: https://www.marketbeat.com/logos/articles/med_20231128191819_jj-gilead-bms-a-look-at-undervalued-dividend-payer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL2ZoYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9e758a18ead9bfe0dc993521a744e138a7625d8d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231128191819_jj-gilead-bms-a-look-at-undervalued-dividend-payer.jpg?locale=us)
J&J, Gilead, BMS: A look at undervalued dividend payers
Johnson & Johnson (NYSE: JNJ), Gilead Sciences Inc. (NYSE: GILD) and Bristol Myers Squibb Co. (NYSE: BMY) are among healthcare sector dividend-payers trading at low valuations relative to their
![J&J, Gilead, BMS: A look at undervalued dividend payers: https://www.marketbeat.com/logos/articles/med_20231128191819_jj-gilead-bms-a-look-at-undervalued-dividend-payer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL2ZoYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9e758a18ead9bfe0dc993521a744e138a7625d8d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231128191819_jj-gilead-bms-a-look-at-undervalued-dividend-payer.jpg?locale=us)
J&J, Gilead, BMS: A look at undervalued dividend payers
Johnson & Johnson (NYSE: JNJ), Gilead Sciences Inc. (NYSE: GILD) and Bristol Myers Squibb Co. (NYSE: BMY) are among healthcare sector dividend-payers trading at low valuations relative to their
![BellRing Brands gets pumped on the Ozempic weight-loss trend: https://www.marketbeat.com/logos/articles/med_20231126113844_chart-brbr.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0xmYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d6a8c22f1584e9975545442ba854fc45545ae133/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231126113844_chart-brbr.jpg?locale=us)
BellRing Brands gets pumped on the Ozempic weight-loss trend
Sports nutritional products maker BellRing Brands Inc. (NYSE: BRBR) has seen its stock surge to new all-time highs driven by the popularity of GLP-1 weight-loss medication usage. While the name of
![Medtronic: oversold, overextended high yield reversal in play: https://www.marketbeat.com/logos/articles/med_20231121185742_medtronic-oversold-overextended-high-yield-reversa.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBekRkYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6fcd99f44ac695af8838b8ab678ab87a88a6dbcc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231121185742_medtronic-oversold-overextended-high-yield-reversa.jpg?locale=us)
Medtronic: oversold, overextended high yield reversal in play
After two years of correction and downtrend, providing ample incentive to buyers all along the way, medical device maker Medtronic (NYSE: MDT) has finally reached its bottom, and the reversal is
![Safeguard your portfolio with these three bargain stocks: https://www.marketbeat.com/logos/articles/med_20231120184155_safeguard-your-portfolio-with-these-three-bargain.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1BjYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--16d72789de22ff6a78648a3716df9e6b46586c86/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231120184155_safeguard-your-portfolio-with-these-three-bargain.jpg?locale=us)
Safeguard your portfolio with these three bargain stocks
Welcome to the jungle. Today's stock market is not the one you inherited from your parents or even your grandparents. In prior generations, information took a bit longer to spread across sectors
![Safeguard your portfolio with these three bargain stocks: https://www.marketbeat.com/logos/articles/med_20231120184155_safeguard-your-portfolio-with-these-three-bargain.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1BjYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--16d72789de22ff6a78648a3716df9e6b46586c86/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231120184155_safeguard-your-portfolio-with-these-three-bargain.jpg?locale=us)
Safeguard your portfolio with these three bargain stocks
Welcome to the jungle. Today's stock market is not the one you inherited from your parents or even your grandparents. In prior generations, information took a bit longer to spread across sectors
![4 high yields near 52-week lows worth looking at: https://www.marketbeat.com/logos/articles/med_20231113110019_chart-wba-11132023ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMkRVYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a1fc8a00314301018561161b2336703ccff65e1e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231113110019_chart-wba-11132023ver001.png?locale=us)
4 high yields near 52-week lows worth looking at
Marketbeat's stock screening tools are a wealth of investment ideas, including the 52-week low list. Stocks trading at 52-week lows often provide oversold value ready to spring back, given the
![4 high yields near 52-week lows worth looking at: https://www.marketbeat.com/logos/articles/med_20231113110019_chart-wba-11132023ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMkRVYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a1fc8a00314301018561161b2336703ccff65e1e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231113110019_chart-wba-11132023ver001.png?locale=us)
4 high yields near 52-week lows worth looking at
Marketbeat's stock screening tools are a wealth of investment ideas, including the 52-week low list. Stocks trading at 52-week lows often provide oversold value ready to spring back, given the
![3 Dividend Champions with room for dividend growth: https://www.marketbeat.com/logos/articles/med_20231110113832_3-dividend-champions-with-room-for-dividend-growth.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0RUYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fbf06ab40dff23457a16966fc5b6eb94f89bb974/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231110113832_3-dividend-champions-with-room-for-dividend-growth.jpg?locale=us)
3 Dividend Champions with room for dividend growth
The World Series champion Texas Rangers recently paid nice dividends for sports bettors. For stock investors, there's a different, more predictable group of dividend payers worth betting on — the
![Why you can make Vertex Pharmaceuticals a buy on any pullback: https://www.marketbeat.com/logos/articles/med_20231108101211_why-you-can-make-vertex-a-buy-on-any-pullback.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzNPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cae87a8fc2648781a3d08aa5a867ec77b03270cc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231108101211_why-you-can-make-vertex-a-buy-on-any-pullback.jpg?locale=us)
Why you can make Vertex Pharmaceuticals a buy on any pullback
Shares of Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a
![Why you can make Vertex Pharmaceuticals a buy on any pullback: https://www.marketbeat.com/logos/articles/med_20231108101211_why-you-can-make-vertex-a-buy-on-any-pullback.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzNPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cae87a8fc2648781a3d08aa5a867ec77b03270cc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231108101211_why-you-can-make-vertex-a-buy-on-any-pullback.jpg?locale=us)
Why you can make Vertex Pharmaceuticals a buy on any pullback
Shares of Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a